Huperzine A (HA), a potent reversible inhibitor of
acetylcholinesterase (AChE), is an important
psychotherapeutic agent for improving cognitive function in
Alzheimer's patients through the enhancement of central
cholinergic tone. This molecule takes on added value in that it
has recently been shown to exhibit neuroprotective
properties (glutamate toxicity blocking activity) in vitro.
Based upon our cumulative SAR information and to some
extent the predicted binding site of HA within Torpedo AChE,
we chose to investigate the synthesis and biology of
certain C-10 substituted analogues. The important finding was made
that introduction of an axial methyl group into
the C-10 position of huperzine A increased the potency for AChE
inhibition 8-fold; the corresponding equatorial
isomer was about 1.5-fold less active than huperzine A. The
introduction of substituents larger than methyl resulted
in a drop in activity. For example, the ethyl analogue was found
to be about 100-fold less active than huperzine A,
indicating that while it is still capable of binding to Torpedo
AChE, some steric interaction with the “walls” of
the
active site gorge must result. Through the use of molecular
modeling methods involving the docking of these analogues
to the reported X-ray crystal structure of Torpedo AChE, it
is clearly evident that the C-10 axial methyl group points
into a hydrophobic region of the enzyme, while the equatorial methyl
group is directed to a less favorable hydrophilic
region. Substituents larger than methyl were found to result in a
conformational energy penalty. The ready explanation
of this structure−activity relationship data provides further
evidence in support of our modeling studies aimed at
establishing huperzine A's binding site in AChE. This knowledge
should facilitate the identification of other structural
analogues of huperzine A likely to exhibit an improved therapeutic
profile.